Electromedical T Stock Price, News & Analysis

Electromedical Technologies, Inc. (OTCQB: EMED) announced the launch of two weekly marketing events starting May 26, 2021, following a successful Facebook Live testimonial event. Led by Sales Director Kathy Strand R.N., these sessions aim to enhance product awareness and onboard new distributors. The Wednesday events will feature testimonials from healthcare professionals and patients on the WellnessPro Plus® device, while Thursdays will focus on distributor training. The company targets onboarding 200 active distributors by year-end 2021.

Electromedical Technologies, Inc. (OTCQB: EMED) is set to host its inaugural Facebook Live event on May 19, 2021, at 2:20 PM CST. The event will feature chiropractor Dr. Jeff Harper discussing the benefits of the WellnessProPlus®, a non-invasive device designed for chronic pain relief. This initiative aims to enhance awareness and sales of the company's bioelectronic products while onboarding new distributors. EMED focuses on developing advanced medical devices cleared by the FDA, specifically for treating various pain conditions.

Electromedical Technologies, Inc. (EMED) announces the appointment of Kathy Strand, R.N. as Director of Sales and Training. Strand brings 12 years of experience, having sold over 3,000 WellnessPro+ devices and treated more than 28,000 patients. EMED aims to onboard 200 active sales distributors by year-end, with 37 already added in 2021. The company expects increased product awareness and sales as Strand focuses on education and outreach efforts. CEO Matthew Wolfson emphasized her critical role in expansion plans for the WellnessPro+.

Electromedical Technologies, Inc. (OTCQB: EMED) has entered Phase 2 of developing the WellnessPro POD™ device, focusing on efficacy and product integration testing, expected to conclude by Fall 2021. This device aims to provide a non-opioid solution for chronic pain management, targeting mass-market retail customers. The upcoming FDA 510(k) submission reflects the company’s commitment to addressing the opioid crisis. CEO Matthew Wolfson highlights the potential for EMED to capture significant market share by offering safe, drug-free pain relief alternatives.

Electromedical Technologies, Inc. (OTCQB: EMED) announced that CEO Matthew Wolfson was featured in three recent interviews on the Big Biz Radio Show. This exposure has helped the company reach a broader audience interested in bioelectronic devices, especially for chronic pain treatments. Wolfson discussed the Wellness POD, a new prototype device expected to be submitted for FDA approval later this year. The company continues to focus on developing innovative treatments for pain relief and improving human wellbeing through advanced research.

Electromedical Technologies, Inc. (OTCQB: EMED) addresses promotional activity regarding its stock initiated by Epic Stock Picks, which occurred on March 17, 2021. The company clarified it did not authorize or fund the promotion and has no involvement with Epic Stock Picks. Although trading volume increased post-promotion, the firm remains unacquainted with its impact. EMED is committed to educating the public about its FDA-cleared Wellness Pro™ product and emphasized the misleading nature of Epic Stock Picks' claims due to omission of significant risk factors from their communications.

Electromedical Technologies, Inc. (OTCQB: EMED) announced securing a $1 million investment from Yorkville Advisors for the prototype production of its WellnessPlus POD. This new device aims at affordable pain relief solutions for the mass market and is set for FDA submission in 2021. The company emphasizes its commitment to assist Veterans and First Responders, offering devices with no upfront cost. CEO Matthew Wolfson noted the funding as pivotal for their development goals amidst the worsening opioid epidemic.

Electromedical Technologies, Inc. (OTCQB: EMED) has secured a $1 million investment from Yorkville Advisors to produce its WellnessPlus POD prototype. This device aims for FDA 510(k) submission later in 2021, facilitating access to affordable electrotherapy for chronic pain relief. The WellnessPlus POD will target mass market retail consumers and provide special programs for veterans and first responders. Company representatives express optimism about the product's potential impact and market readiness. The initiative is part of EMED's broader strategy to address the opioid crisis through non-drug solutions.

Electromedical Technologies (OTCQB: EMED) has successfully completed its uplisting to the OTCQB exchange, aiming to meet higher compliance standards and attract institutional investment. The global pain management device market is projected to reach $11.3 billion by 2025, driven by increasing chronic pain among elderly and obese populations. CEO Matthew Wolfson highlighted the urgency for alternative pain treatments amid the opioid crisis, exacerbated by the pandemic. EMED's bioelectronic device technology is expected to significantly improve quality of life and health without addictive side effects.